膀胱癌细胞癌基因ras产物P_(21)的表达及其临床意义

本文用癌基因ras产物P_(21)的单克隆抗体SCI-oncogema 1及ABC免疫酶标染色法对53例膀胱癌和7例泌尿系非肿瘤病人的膀胱粘膜石蜡切片进行染色,结合肿瘤的病理学分级和分期以及病人随访结果进行分析,表明弱例膀胱癌中P_(21)阳性者达32例(60.4％),而7例泌尿系非肿瘤病人的膀胱粘膜标本其P_(21)均为阴性。还发现在膀胱癌P_(21)的阳性率随着病理分级和分期的上升而明显下降,P_(21)阳性膀胱癌其复发率为17.6％,而P_(21)阴性膀胱癌的复发率则高达82.4％。经分析还发现P_(21)表达与膀胱癌预后有密切的相关性,32例P_(21)阳性膀胱癌患者中死于肿瘤者仅3例(9.4％),而21例P_(21)阴性膀胱癌患者中死于肿瘤者多达17例(81％)。提示P_(21)阳性可考虑作为膀胱癌预后较好的客观依据之一。

THE SIGNIFICANCE OF THE EXPRESSION OF ras ONCOGENE P_(21) IN BLADDER CANCER

Paraffin-embedded tumor sections from 53 patients with bladder oaneer, and paraffin-embedded bladder mucosa sections from 7 patients with non-neoplastic urologic diseases were taken and stained with SGI-oncpgema 1, a monoclonal antibody against ras oncoprotein P21, and ABO immunohistochemioal procedures. The results were analysed in combination with the histopathologioal grading and slage of the tumors and the outcome of patients. The P21 expression was positive in 32 of the 53 cases (60.4%) with bladder cancer, and negative in all 7 oases with non-neoplastic urologio diseases. We also found that the rates of P21 positive expression decreased with higher tumor grades and stages. Recurrent rates for tumor cases with P21 positive expression was 17.6% and 82 A % for cases with negative P21 expressions. Follow-up analysis revealed that there was a close correlation between the expression of P21 and prognosis. In the 32 patients with P21 positive expression only 3 (9.4%) died of tumor spread and in 21 patients with negative P21 expression 17 (81%) died of tumor spread, indicating that P21 positive expression is a good prognostic parameter for patients with bladder cancer.